Biotech news
Biotech
Biotech claims action was necessary due to unfavourable rulings after being targeted by a rival | Accuses gene technology firm of attempting to shrink the competitive landscape for different spatial biology platforms. 6 February 2024
Pharma
PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation. 1 February 2024
Americas
Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions. 1 February 2024
Biotech
MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body. 30 January 2024
Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival. 25 January 2024
Biotech
Despite the clamour for guidance, applicants, attorneys, and lawyers may be in for a frustrating wait before the UK updates AI protections, says Rebecca Lawrence of DLA Piper. 25 January 2024
Pharma
Complaints say Slayback, Apotex and Baxter Healthcare infringed two patents through NDAs for leukaemia drug injection | Eagle patents issued in last two months expire in 2031. 23 January 2024
Biotech
The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals. 18 January 2024
Biotech
Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal. 18 January 2024
Americas
Biotech company submitted a petition challenging an ‘incorrect’ ruling by the Court of Appeals for the Federal Circuit | Earlier decision invalidated several of Vanda’s patents in its sleep drug dispute against a pair of big pharma firms. 16 January 2024